Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.
about
Recent developments in receptor tyrosine kinases targeted anticancer therapyMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaElucidating Genomic Characteristics of Lung Cancer Progression from In Situ to Invasive AdenocarcinomaDistinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.Utility of Genomic Analysis in Differentiating Synchronous and Metachronous Lung Adenocarcinomas from Primary Adenocarcinomas with Intrapulmonary Metastasis.Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularPulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletionsAdvances on EGFR mutation for lung cancer.Do all lung adenocarcinomas follow a stepwise progression?Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatmentEpidermal growth factor receptor (EGFR) in lung cancer: an overview and update.Neoadjuvant erlotinib and surgical resection of a stage iiia papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation.A growing family: adding mutated Erbb4 as a novel cancer targetIntegrating the multiple dimensions of genomic and epigenomic landscapes of cancer.Risk for molecular contamination of tissue samples evaluated for targeted anti-cancer therapy.Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.Cytogenomics of cancers: from chromosome to sequence.Experience with erlotinib in the treatment of non-small cell lung cancer.Sequencing brain metastases and opportunities for targeted therapies.Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.A therapeutic target for smoking-associated lung cancer.Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas.Mechanisms of receptor tyrosine kinase activation in cancer.PET Imaging-Based Phenotyping as a Predictive Biomarker of Response to Tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer: Are We There Yet?Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas resected at a single institution.Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression.Predictive Tumor Biomarkers for EGFR Inhibitors
P2860
Q26751331-6D3626E7-8192-43BA-940E-E752EA0C2398Q26828860-8AEEF83C-421F-4C16-9DAD-CCD3B3179BF5Q28303718-58296784-656D-44A2-8746-C60578DD65DCQ28387158-DEBC1D13-2A82-4AAB-9D96-2725B09B61FCQ30762699-97A67C02-8699-4018-A26D-456C9F0D2FB8Q33607511-5A55D2ED-A968-4340-ABE7-3643D6F1B40DQ33942092-E1A66A12-D3F3-4A87-B159-E531196B8E43Q34159011-3C60B0EE-0B0F-43C6-AF77-A3E4825EE2B5Q34404209-302C48FF-13BA-446F-A58A-40803961FD71Q34762342-120B7968-7BE9-4E31-81CA-8C39056040E0Q35200375-667B3AF6-6806-4B75-A03E-ADA74E5B4727Q35211197-C20AE96E-D5EC-4D9C-81E6-D4B1926E73BDQ35227986-039046B7-92D8-48CC-83EA-AC4ABF9B6B6FQ35667627-3C547539-1A47-4644-B627-ACCA64190BDCQ36000269-826EAE76-7F2D-44D4-AB2C-86280803B6C7Q36062442-4F5D22EA-06CD-45AD-8503-EF1FD3F765FEQ36152246-5D585463-76DD-4A78-AAC3-C8349F3C2325Q36306292-B066B104-F4AB-4E09-8DDB-1ACBEDEEFE36Q36546095-57E38C11-351D-4C64-A0FA-BBA5ABB2DC49Q37769763-15F858FD-8DD7-474C-A5DF-8355CAB57739Q38524526-FA0B9DD1-B26D-4C69-BF2C-E4C992EE2828Q39177404-BEB9898B-5293-4259-A962-3999B1FC8F12Q39281214-8A16452C-688A-4ABB-B195-C5427F3841B6Q39619712-DBF2659E-55B5-4B9C-8DA9-24F1690D2637Q40393934-F385F7E2-06DA-4C83-87A7-AD4B50260037Q41233667-E07374B2-7013-451C-B0E7-403874F5E4CFQ49888000-FFC9875E-F2F8-4635-A8B6-4A3C9D85F281Q50326521-FEB19B35-C4DA-4898-984A-8A596B4CA908Q54388141-2EFE3298-CB91-4187-ABE0-D7CE10D4987DQ54980290-999C3A89-0306-4C8E-9CC2-6A9BA5A92241Q57896476-084B0AE6-2DF1-4DA6-9A51-7F00C7DC8E5D
P2860
Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lung adenocarcinoma with EGFR ...... lar features in never-smokers.
@en
Lung adenocarcinoma with EGFR ...... lar features in never-smokers.
@nl
type
label
Lung adenocarcinoma with EGFR ...... lar features in never-smokers.
@en
Lung adenocarcinoma with EGFR ...... lar features in never-smokers.
@nl
prefLabel
Lung adenocarcinoma with EGFR ...... lar features in never-smokers.
@en
Lung adenocarcinoma with EGFR ...... lar features in never-smokers.
@nl
P2093
P2860
P1433
P1476
Lung adenocarcinoma with EGFR ...... lar features in never-smokers.
@en
P2093
A John Iafrate
Alison J Holmes-Tisch
Beow Y Yeap
David C Christiani
Elisa Benedettini
Lucian R Chirieac
Lynette M Sholl
Ming-Tsang Wu
P2860
P304
P356
10.1158/0008-5472.CAN-09-2477
P407
P577
2009-10-13T00:00:00Z